Format

Send to

Choose Destination
Acta Biochim Biophys Sin (Shanghai). 2015 Nov;47(11):925-31. doi: 10.1093/abbs/gmv094. Epub 2015 Sep 9.

Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.

Author information

1
Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
2
Department of Internal Medicine, University of Iowa, Carver College of Medicine, Iowa City IA 52242, USA.
3
School of Life Science and Technology, Tongji University, Shanghai 200092, China.
4
Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China wux163@163.com shijumei@tongji.edu.cn.

Abstract

Fucoidan is one of the major sulfated polysaccharides isolated from brown seaweeds. In this study, we determined the anti-cancer activity of fucoidan on diffuse large B cell lymphoma (DLBCL) cells both in vitro and in vivo. Fucoidan inhibited the growth of DLBCL cells in a dose- and time-dependent manner, and fucoidan treatment provoked G0/G1 cell cycle arrest, which was accompanied by p21 up-regulation and cyclin D1, Cdk4, and Cdk6 down-regulation. Fucoidan also induced caspase-dependent cell apoptosis in DLBCL cell lines and primary DLBCL cell. In addition, fucoidan treatment caused the loss of mitochondrial membrane potential and the release of cytochrome c and apoptosis-inducing factor from the mitochondria into the cytosol. Fucoidan also potentiated the activities of carfilzomib in killing DLBCL cells. Oral administration of fucoidan effectively inhibited tumor growth in xenograft mouse models. Our findings reveal the novel function of fucoidan as an anti-DLBCL agent, which can be used in the clinical treatment of DLBCL.

KEYWORDS:

apoptosis; cell cycle; diffuse large B cell lymphoma; fucoidan

PMID:
26358321
DOI:
10.1093/abbs/gmv094
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center